rosuvastatin

(redirected from rosuvastatin calcium)
Also found in: Medical.

ro·su·va·stat·in

 (rŏ-so͞o′və-stăt′n)
n.
A statin drug, C22H28FN3O6S, used in the form of its calcium salt to lower cholesterol (especially LDL) levels and to reduce the risk of heart attack and stroke in individuals with elevated risk.

[Perhaps (fluo)ro- + su(lfonyl) + -vastatin, statin suffix; see pravastatin.]
Translations

rosuvastatin

n rosuvastatina
References in periodicals archive ?
Tenders are invited for Substance Rosuvastatin calcium (Mandatory requirements: manufacturer Teva Assia Chemical Industries Ltd, Israel - ND RB 1335C-2014; Residual shelf life of the goods on the date of delivery should be at least 80% of the total shelf life)
5% ointment; and rosuvastatin calcium tablets in 5, 10, 20 and 40 mg bases.
M2 EQUITYBITES-July 25, 2016-Citron Pharma receives US FDA Abbreviated New Drug Application approval for Rosuvastatin Calcium 5, 10, 20 and 40 mg tablets
M2 PHARMA-July 25, 2016-Citron Pharma receives US FDA Abbreviated New Drug Application approval for Rosuvastatin Calcium 5, 10, 20 and 40 mg tablets
Rosuvastatin calcium tablets (Crestor 5 mg, AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) were mixed at a proportion of 1 tablet per 0.
Tenders are invited for Rosuvastatin Calcium 5 Mg Tab.
Pharmaceutical company Mylan NV (NASDAQ:MYL) (TASE:MYL) reported on Wednesday the availability of Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg in the US market.
According to Actavis, the deal resolves outstanding patent litigation related to its rosuvastatin calcium 5-, 10-, 20- and 40-mg tablets, the generic version of AstraZeneca's Crestor tablets, as well as Actavis' rosuvastatin zinc alternate salt product.
Since 2007, nine generic drug makers have filed abbreviated new drug applications (ANDAs) for copy-cat versions of Crestor, claiming non-infringement, invalidity or unenforceability of the RE37,314, or the 314 patent, protecting the active ingredient rosuvastatin calcium.
The tentative USFDA approval for Rosuvastatin calcium tablets heralds our entry into the US generics market.
Pharmaceutical company Allergan (NYSE:AGN) revealed on Monday that it has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for rosuvastatin calcium 5, 10, 20 and 40 mg tablets.